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Background

Results

Twelve percent of women suffer from breast cancer each year, but
survivorship is increasing due to improvements in treatments.
However it appears there are lasting effects after treatment due to
the toxicity of chemotherapy compounds. One of the most severe
side effects is chemotherapy induced peripheral neuropathy
(CIPN) which results in a decreased sensation in the nervous
system. With this loss, an individual’s balance and postural
stability is likely impacted, leading to an altered quality of life.
Monfort et al. at The Ohio State University are among the first to
identify balance deficits in breast cancer patients during treatment,
even after the first treatment cycle [1]. We joined with them as
they extended this work to include long-term follow up testing after
completion of treatment. Our efforts specifically investigate the
effects of treatments on dynamic and static postural stability, range
of motion, and balance control looking at variances between
individuals with different treatments and symptoms.
Hypothesis: Significant balance impairments would occur in all
those who received neurotoxic chemotherapy, however more
intensified impairments will occur in those who had chemotherapy
and signs of CIPN.
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Methods
3 subjects groups tested after treatment and 6 months post
treatment: control (those with cancer without neurotoxic
chemotherapy (n=6, 5 testing complete), asymptomatic (those with
cancer, neurotoxic chemotherapy, and no reported CIPN (n=8, 3
testing complete)), and symptomatic (those with cancer and
neurotoxic chemotherapy with signs of CIPN (n=7, 3 testing
complete)
3 hour data collection period : Overground and treadmill walking,
static and dynamic balance tests on a balance plate.
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Conclusions
The symptomatic group had varied individual sway responses 6 months post treatment,
however showed slight improvement in their average time to contact. Further data analysis
is required, however the current results suggests that interventions to improve postural
stability for the symptomatic group may be warranted.

Figure 1: Limits of Stability Tests [2]
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